DOCSLIB.ORG

Multifaceted Functions of Prokineticins in Reproductive Cancers And

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Multifaceted Functions of Prokineticins in Reproductive Cancers And J Cancer Sci Clin Ther 2020; 4 (4): 408-423 DOI: 10.26502/jcsct.5079082 Review Article Multifaceted Functions of Prokineticins in Reproductive Cancers and Proposed Associated Therapies Constance Collet1,2,3#, Roland Abi Nahed1,2,3#, Kevin Gemy1,2,3,4, Wael Traboulsi5, Nicolas Lemaitre1,2,3, Pierre-Adrien Bolze6,7, Pascale Hoffmann8, Mohamed Benharouga2,3,4, Nadia Alfaidy1,2,3* #Authors contributed equally 1Institut National de la Santé et de la Recherche Médicale, Unité 1036, Grenoble, France 2University Grenoble-Alpes, 38000, Grenoble, France 3Commissariat à l’Energie Atomique et aux Energies Alternatives (CEA), Biosciences and Biotechnology Institute of Grenoble, Grenoble, France 4Centre National de la Recherche Scientifique, Unité Mixte de Recherche 5249, Laboratoire de Chimie et Biologie des Métaux, Grenoble, France 5Georgetown University Medical Center, Pre-Clinical Science Building, GD01/office number, 3900 Reservoir Rd NW, Washington DC 20007 6University of Lyon 1, University Hospital Lyon Sud, Department of Gynecological Surgery and Oncology, France 7French Reference Center for Gestational Trophoblastic Diseases, University Hospital Lyon Sud, 165, Chemin du Grand Revoyet, 69495 Pierre Bénite, France 8University Hospital of Grenoble, Department of Obstetrics and Gynaecology, and Laboratoire d’Aide à la Procréation- CECOS, La Tronche, France *Corresponding Author: Dr. Nadia Alfaidy, Unité INSERM U1036. Laboratoire BCI –Biosanté, CEA Grenoble 17, rue des Martyrs, 38054 Grenoble cedex 9, France, Tel: 0438783501; Fax: 0438785058; E-mail: [email protected] Received: 29 June 2020; Accepted: 17 August 2020; Published: 02 October 2020 Citation: Constance Collet, Roland Abi Nahed, Kevin Gemy, Wael Traboulsi, Nicolas Lemaitre, Pierre-Adrien Bolze, Pascale Hoffmann, Mohamed Benharouga, Nadia Alfaidy. Multifaceted Functions of Prokineticins in Reproductive Cancers and Proposed Associated Therapies. Journal of Cancer Science and Clinical Therapeutics 4 (2020): 408-423. Journal of Cancer Science and Clinical Therapeutics 408 J Cancer Sci Clin Ther 2020; 4 (4): 408-423 DOI: 10.26502/jcsct.5079082 Abstract 1. Prokineticin Family Prokineticin 1 and prokineticin 2 are two secreted proteins In mammals, the prokineticin family is composed of two that belong to the prokineticin family. The two ligands act members, the prokineticin 1 (PROK1) also called EG- via two G protein-coupled receptors, PROKR1 and VEGF (Endocrine Gland-derived Vascular Endothelial PROKR2 to induce cell’s proliferation, migration, invasion Growth Factor) and the prokineticin 2 (PROK2) also called and permeability. They mostly act on epithelial, endothelial Bv8 [1, 2]. EG-VEGF is transcribed from the prok1 gene and immune cells. Deregulations in the expression of the composed of three exons located on chromosome 1 in 1p21 ligands and/or the receptors of this family have been [3, 4]. The gene that transcribes PROK2 is located on the associated with both tumor and non-tumor pathologies of chromosome 3 at 3p13. the reproductive system. In these pathologies, prokineticins have been reported to be associated with strong angiogenic Prokineticins and their receptors are expressed in various and inflammatory activities. While their direct involvement tissues such as ovary, testis, adrenal gland, placenta, uterus, in some threatening reproductive non-tumor pathologies brain, digestive tract and bone marrow [5-7]. In many such as kallmann syndrome, polycystic ovaries, organs prokineticin’s expression has been shown to be preeclampsia and fetal growth restriction are well dynamic throughout physiological processes such as, established, their role and their consideration as potential circadian rhythm [8] menstrual cycle [9] and throughout targets in the tumors of the reproductive system are stil pregnancy [10, 11]. In these systems, prokineticins have debated. This review will address the multifaceted roles of been shown to be regulated by local effectors and/or prokineticins and their receptors in reproductive cancers. endocrine hormones. In the ovaries PROK1 is regulated by Especially, the review will address the role of the -hCG (human Chorionic Gonadotropin), estrogen and prokineticin system in two female cancers, the ovarian FSH [12-14]. In the placenta PROK1 has been shown to be cancer and the gestational cancer, Choriocarcinoma. The regulated by hypoxia, hCG and PPAR [10, 15, 16]. two types of cancer differentially express the prokineticin ligands at their early developmental stages, leading to The prokineticins are secreted protein that act through their different overall responses to be adapted when binding to two G protein-coupled receptors (GPCRs) [1, 2], antagonisation of the prokineticin system is proposed. The the prokineticin receptor 1 (PROKR1) and the prokineticin review will summarize recent advances in the receptor 2 (PROKR2). The prokineticin receptors were understanding of the prokineticin system’s involvement in discovered simultaneously by three research teams [1, 2]. the reproductive cancers, discuss its multifaceted roles in They belong to the GPCR family, with seven relation to prokineticin’s actions and proposes associated transmembrane domains that interact with heterotrimeric G therapies. proteins. PROKR1 and PROKR2 were initially called GPR73A and B, then receptors of prokineticin 1 and Keywords: Prokineticin; Reproductive cancer; Targeted prokineticin 2, respectively. They share 85% homology in therapies; Immune system; Prokineticin antagonists their amino acid sequence, but differ in their N-terminal parts [1, 2, 17]. Journal of Cancer Science and Clinical Therapeutics 409 J Cancer Sci Clin Ther 2020; 4 (4): 408-423 DOI: 10.26502/jcsct.5079082 Strong similarities were found in their transmembrane 2. Prokineticins and Diseases domains, suggesting similarities in their mechanisms of Prokineticins were first identified as potent agents activation [17]. In human, the prokr1 and prokr2 genes stimulating the muscle contraction of the gastrointestinal include two exons and are located on two different tract [14, 21]. Later, PROK1 was shown to mediate chromosomes. The prokr2 gene is located on chromosome proliferation and differentiation of the enteric neural crest 2 at 2q14 and prokr1 gene is located on chromosome 20 at cells during the enteric nervous system (ENS) development 20p13 [1]. The two prokineticins act as powerful ligands for [22]. Since their discovery, prokineticin proteins have been both PROKR1 and PROKR2 receptors. Interestingly, associated with two key biological functions, angiogenesis, differential and tissue-specific expressions were reported including vascular remodeling, and inflammation [6, 23, for the two receptors. PROKR2 is abundantly expressed in 24]. Over the last two decades, research articles on the the brain and testes, while PROKR1 is mainly expressed in prokineticins have either studied their role in angiogenesis peripheral tissues such as the spleen, prostate, pancreas, and neovascularization or in inflammation [6, 23, 24]. heart and blood cells. In the reproductive system, high However, few studies have addressed combined actions of levels of both receptors have been reported in the testis, the prokineticins in a given physiological or pathological ovary, endometrium and placenta [6, 9, 12, 18, 19]. process. Several studies have been carried out to determine the A determinant factor that links the biology of prokineticins affinity of the two ligands to their receptors. It clearly with vascular remodeling is the hypoxic environment which appears that PROK2 exhibits higher affinity for PROKRs develops upon a vascular damage and which is known to (EC50 of 4.5 ± 0.8 nmol/L for PROKR1 and 6.4 ± 1.3 up-regulate prokineticins. Importantly, both PROK1 and nmol/L for PROKR2) [20], whereas PROK1 exhibits a PROK2 promoter regions have response elements for the moderate affinity for both receptors (EC50 of 27.6 ± 8.2 hypoxia inducible factor (HIF-1) [6, 23, 24]. In several nmol/L for PROKR1 and 52.2 ± 16.4 nmol/L for studies, prokineticins have been reported as potent PROKR2). Distinct expression patterns of the prokineticins angiogenic factors and their receptors are highly expressed and their receptors have been reported in various tissues, in both microvascular and macrovascular endothelial cells providing the cue for their tissue-specific biological [6, 23]. functions [5-7]. In addition, the differential pattern of expression of G-proteins plus the multiple types of G- PROK1 was reported as a potent angiogenic factor that proteins that can couple to these receptors further increase promotes angiogenesis in various steroidogenic glands [4, the functional complexity of the system. PROK1 and 8, 10]. In relation to inflammatory processes, both ligands PROK2 bind to PROKR1 and PROKR2, which can be were reported to activate this process. However, unlike coupled to Gi, Gs and Gq to activate MAPK/Akt, induce PROK1, PROK2 is more associated with this process as it cAMP accumulation and calcium mobilization [20]. is expressed in the bone marrow. PROK2 is also reported as the preferential prokineticin expressed by immune cells as it acts as a potent chemoattractant for monocytes and Journal of Cancer Science and Clinical Therapeutics 410 J Cancer Sci Clin Ther 2020; 4 (4): 408-423 DOI: 10.26502/jcsct.5079082 neutrophils [24, 25]. It also induces survival, differentiation clinical, in vitro, ex vivo, and in vivo studies [6, 10, 16, 33- and activation of the granulocytic and monocytic 36]. Through its receptors PROKR1 and
Load more

Recommended publications
  • Searching for Novel Peptide Hormones in the Human Genome Olivier Mirabeau
    Searching for novel peptide hormones in the human genome Olivier Mirabeau To cite this version: Olivier Mirabeau. Searching for novel peptide hormones in the human genome. Life Sciences [q-bio]. Université Montpellier II - Sciences et Techniques du Languedoc, 2008. English. tel-00340710 HAL Id: tel-00340710 https://tel.archives-ouvertes.fr/tel-00340710 Submitted on 21 Nov 2008 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. UNIVERSITE MONTPELLIER II SCIENCES ET TECHNIQUES DU LANGUEDOC THESE pour obtenir le grade de DOCTEUR DE L'UNIVERSITE MONTPELLIER II Discipline : Biologie Informatique Ecole Doctorale : Sciences chimiques et biologiques pour la santé Formation doctorale : Biologie-Santé Recherche de nouvelles hormones peptidiques codées par le génome humain par Olivier Mirabeau présentée et soutenue publiquement le 30 janvier 2008 JURY M. Hubert Vaudry Rapporteur M. Jean-Philippe Vert Rapporteur Mme Nadia Rosenthal Examinatrice M. Jean Martinez Président M. Olivier Gascuel Directeur M. Cornelius Gross Examinateur Résumé Résumé Cette thèse porte sur la découverte de gènes humains non caractérisés codant pour des précurseurs à hormones peptidiques. Les hormones peptidiques (PH) ont un rôle important dans la plupart des processus physiologiques du corps humain.
    [Show full text]
  • Deletion of Vax1 from Gonadotropin-Releasing Hormone (Gnrh) Neurons Abolishes Gnrh Expression and Leads to Hypogonadism and Infertility
    3506 • The Journal of Neuroscience, March 23, 2016 • 36(12):3506–3518 Cellular/Molecular Deletion of Vax1 from Gonadotropin-Releasing Hormone (GnRH) Neurons Abolishes GnRH Expression and Leads to Hypogonadism and Infertility Hanne M. Hoffmann,1 Crystal Trang,1 Ping Gong,1 Ikuo Kimura,2 Erica C. Pandolfi,1 and XPamela L. Mellon1 1Department of Reproductive Medicine and the Center for Reproductive Science and Medicine, University of California, San Diego, La Jolla, California 92093-0674, and 2Department of Applied Biological Science, Graduate School of Agriculture, Tokyo University of Agriculture and Technology, Fuchu-shi 183-8509, Japan Hypothalamic gonadotropin-releasing hormone (GnRH) neurons are at the apex of the hypothalamic-pituitary-gonadal axis that regu- lates mammalian fertility. Herein we demonstrate a critical role for the homeodomain transcription factor ventral anterior homeobox 1 (VAX1) in GnRH neuron maturation and show that Vax1 deletion from GnRH neurons leads to complete infertility in males and females. Specifically, global Vax1 knock-out embryos had normal numbers of GnRH neurons at 13 d of gestation, but no GnRH staining was detected by embryonic day 17. To identify the role of VAX1 specifically in GnRH neuron development, Vax1flox mice were generated and lineage tracing performed in Vax1flox/flox:GnRHcre:RosaLacZ mice. This identified VAX1 as essential for maintaining expression of Gnrh1. The absence of GnRH staining in adult Vax1flox/flox:GnRHcre mice led to delayed puberty, hypogonadism, and infertility. To address the mechanism by which VAX1 maintains Gnrh1 transcription, the capacity of VAX1 to regulate Gnrh1 transcription was evaluated in the GnRH cell lines GN11 and GT1-7.
    [Show full text]
  • Loss-Of-Function Mutation in the Prokineticin 2 Gene Causes
    Loss-of-function mutation in the prokineticin 2 gene SEE COMMENTARY causes Kallmann syndrome and normosmic idiopathic hypogonadotropic hypogonadism Nelly Pitteloud*†, Chengkang Zhang‡, Duarte Pignatelli§, Jia-Da Li‡, Taneli Raivio*, Lindsay W. Cole*, Lacey Plummer*, Elka E. Jacobson-Dickman*, Pamela L. Mellon¶, Qun-Yong Zhou‡, and William F. Crowley, Jr.* *Reproductive Endocrine Unit, Department of Medicine and Harvard Reproductive Endocrine Science Centers, Massachusetts General Hospital, Boston, MA 02114; ‡Department of Pharmacology, University of California, Irvine, CA 92697; §Department of Endocrinology, Laboratory of Cellular and Molecular Biology, Institute of Molecular Pathology and Immunology, University of Porto, San Joa˜o Hospital, 4200-465 Porto, Portugal; and ¶Departments of Reproductive Medicine and Neurosciences, University of California at San Diego, La Jolla, CA 92093 Communicated by Patricia K. Donahoe, Massachusetts General Hospital, Boston, MA, August 14, 2007 (received for review May 8, 2007) Gonadotropin-releasing hormone (GnRH) deficiency in the human associated with KS, although no functional data on the mutant presents either as normosmic idiopathic hypogonadotropic hypo- proteins were provided (17). Herein, we demonstrate that homozy- gonadism (nIHH) or with anosmia [Kallmann syndrome (KS)]. To gous loss-of-function mutations in the PROK2 gene cause IHH in date, several loci have been identified to cause these disorders, but mice and humans. only 30% of cases exhibit mutations in known genes. Recently, murine studies have demonstrated a critical role of the prokineticin Results pathway in olfactory bulb morphogenesis and GnRH secretion. Molecular Analysis of PROK2 Gene. A homozygous single base pair Therefore, we hypothesize that mutations in prokineticin 2 deletion in exon 2 of the PROK2 gene (c.[163delA]ϩ [163delA]) (PROK2) underlie some cases of KS in humans and that animals was identified in the proband, in his brother with KS, and in his deficient in Prok2 would be hypogonadotropic.
    [Show full text]
  • Signaling Role of Prokineticin 2 on the Estrous Cycle of Female Mice
    Signaling Role of Prokineticin 2 on the Estrous Cycle of Female Mice The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Xiao, Ling, Chengkang Zhang, Xiaohan Li, Shiaoching Gong, Renming Hu, Ravikumar Balasubramanian, William F. Crowley W. Jr., Michael H. Hastings, and Qun-Yong Zhou. 2014. “Signaling Role of Prokineticin 2 on the Estrous Cycle of Female Mice.” PLoS ONE 9 (3): e90860. doi:10.1371/journal.pone.0090860. http:// dx.doi.org/10.1371/journal.pone.0090860. Published Version doi:10.1371/journal.pone.0090860 Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:12064464 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA Signaling Role of Prokineticin 2 on the Estrous Cycle of Female Mice Ling Xiao1,2, Chengkang Zhang1, Xiaohan Li1, Shiaoching Gong3, Renming Hu4, Ravikumar Balasubramanian5, William F. Crowley W. Jr.5, Michael H. Hastings6, Qun-Yong Zhou1* 1 Department of Pharmacology, University of California, Irvine, California, United States of America, 2 Department of Endocrinology, Jinshan Hospital affiliated to Fudan University, Shanghai, China, 3 GENSAT Project, The Rockefeller University, New York, New York, United States of America, 4 Institute of Endocrinology and Diabetology, Huashan Hospital affiliated to Fudan University, Shanghai, China, 5 Harvard Reproductive Endocrine Sciences Center & The Reproductive Endocrine Unit, Massachusetts General Hospital, Boston, Massachusetts, United States of America, 6 Division of Neurobiology, Medical Research Council Laboratory of Molecular Biology, Cambridge, United Kingdom Abstract The possible signaling role of prokineticin 2 (PK2) and its receptor, prokineticin receptor 2 (PKR2), on female reproduction was investigated.
    [Show full text]
  • Orphan G Protein-Coupled Receptors and Obesity
    European Journal of Pharmacology 500 (2004) 243–253 www.elsevier.com/locate/ejphar Review Orphan G protein-coupled receptors and obesity Yan-Ling Xua, Valerie R. Jacksonb, Olivier Civellia,b,* aDepartment of Pharmacology, University of California Irvine, 101 Theory Dr., Suite 200, Irvine, CA 92612, USA bDepartment of Developmental and Cell Biology, University of California Irvine, 101 Theory Dr, Irvine, CA 92612, USA Accepted 1 July 2004 Available online 19 August 2004 Abstract The use of orphan G protein-coupled receptors (GPCRs) as targets to identify new transmitters has led over the last decade to the discovery of 12 novel neuropeptide families. Each one of these new neuropeptides has opened its own field of research, has brought new insights in distinct pathophysiological conditions and has offered new potentials for therapeutic applications. Interestingly, several of these novel peptides have seen their roles converge on one physiological response: the regulation of food intake and energy expenditure. In this manuscript, we discuss four deorphanized GPCR systems, the ghrelin, orexins/hypocretins, melanin-concentrating hormone (MCH) and neuropeptide B/neuropeptide W (NPB/NPW) systems, and review our knowledge of their role in the regulation of energy balance and of their potential use in therapies directed at feeding disorders. D 2004 Elsevier B.V. All rights reserved. Keywords: Feeding; Ghrelin; Orexin/hypocretin; Melanin-concentrating hormone; Neuropeptide B; Neuropeptide W Contents 1. Introduction............................................................ 244 2. Searching for the natural ligands of orphan GPCRs ....................................... 244 2.1. Reverse pharmacology .................................................. 244 2.2. Orphan receptor strategy ................................................. 244 3. Orphan receptors and obesity................................................... 245 3.1. The ghrelin system .................................................... 245 3.2.
    [Show full text]
  • (PROK2) in Alzheimer's Disease
    cells Communication Involvement of the Chemokine Prokineticin-2 (PROK2) in Alzheimer’s Disease: From Animal Models to the Human Pathology Roberta Lattanzi 1, Daniela Maftei 1, Carla Petrella 2, Massimo Pieri 3, Giulia Sancesario 4, Tommaso Schirinzi 5, Sergio Bernardini 3, Christian Barbato 2 , Massimo Ralli 6 , Antonio Greco 6, Roberta Possenti 5, Giuseppe Sancesario 5 and Cinzia Severini 2,* 1 Department of Physiology and Pharmacology “Vittorio Erspamer”, Sapienza University of Rome, P.za A. Moro 5, 00185 Rome, Italy; [email protected] (R.L.); [email protected] (D.M.) 2 Institute of Biochemistry and Cell Biology, IBBC, CNR, Viale del Policlinico, 155, 00161 Rome, Italy; [email protected] (C.P.); [email protected] (C.B.) 3 Department of Experimental Medicine and Surgery, University of Rome Tor Vergata, 00133 Rome, Italy; [email protected] (M.P.); [email protected] (S.B.) 4 Neuroimmunology Unit, IRCCS Santa Lucia Foundation, v. Ardeatina 354, 00179 Rome, Italy; [email protected] 5 Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy; [email protected] (T.S.); [email protected] (R.P.); [email protected] (G.S.) 6 Department of Sense Organs, University Sapienza of Rome, Viale del Policlinico 155, 00161 Rome, Italy; [email protected] (M.R.); [email protected] (A.G.) * Correspondence: [email protected]; Tel.: +39-06-4997-6742 Received: 17 October 2019; Accepted: 12 November 2019; Published: 13 November 2019 Abstract: Among mediators of inflammation, chemokines play a pivotal role in the neuroinflammatory process related to Alzheimer’s disease (AD).
    [Show full text]
  • ACTIVIN IS CRITICAL for the DEVELOPMENT of PAIN HYPERSENSITIVITY AFTER INFLAMMATION by PIN XU Submitted in Partial Fulfillment
    ACTIVIN IS CRITICAL FOR THE DEVELOPMENT OF PAIN HYPERSENSITIVITY AFTER INFLAMMATION by PIN XU Submitted in partial fulfillment of the requirements For the degree of Doctor of Philosophy Thesis Adviser: Dr. Alison K. Hall Department of Neurosciences CASE WESTERN RESERVE UNIVERSITY August, 2007 CASE WESTERN RESERVE UNIVERSITY SCHOOL OF GRADUATE STUDIES We hereby approve the dissertation of ____Pin Xu______________________________________________ candidate for the Ph.D. degree *. (signed)__ Gary Landreth______________________________ ___ (chair of the committee) ___Alison Hall____________________________________ ___Jerry Silver___________ ___________ _____ ___ ___Susann Brady-kalnay____________________________ ________________________________________________ ________________________________________________ (date) ____June 5, 2007___________________ *We also certify that written approval has been obtained for any proprietary material contained therein. ii DEDICATION This thesis is dedicated to my parents, Hongfa Xu and Ruiyun Pan, and to my husband Chen Liu. iii TABLE OF CONTENTS Page Title Page……………………..…………………………………………………….….…I Typed ETD Sign-off Sheet…………………………………………………….................II Dedication……………………………………………………………………………..…III Table of Contents………………………………………………………..……..……..….IV List of Tables……………………………………………………………………………VII List of Figures…………………………………………………………………….....…VIII Acknowledgements………………………………………………………………………X Abstract…………………………………………………………………………...……...XI Chapter I: General Introduction……………………………………………………………………...1 Chapter
    [Show full text]
  • The Role of GPCR Signaling in Cardiac Epithelial to Mesenchymal R, RR Transformation (EMT)
    Trends in Cardiovascular Medicine 29 (2019) 200–204 Contents lists available at ScienceDirect Trends in Cardiovascular Medicine journal homepage: www.elsevier.com/locate/tcm The role of GPCR signaling in cardiac Epithelial to Mesenchymal R, RR Transformation (EMT) ∗ Canan G. Nebigil, PharmD, PhD , Laurent Désaubry, PhD CNRS/Université de Strasbourg, Sorbonne University–CNRS, ESBS Pole API 300 boulevard Sébastien Brant, CS 10413, Paris, Illkirch F-67412, France a r t i c l e i n f o a b s t r a c t Keywords: Congenital heart disease is the most common birth defect, affecting 1.35 million newborns every year. Congenital heart disease Heart failure is a primary cause of late morbidity and mortality after myocardial infarction. Heart devel- Heart development opment is involved in several rounds of epithelial-to-mesenchymal transition (EMT) and mesenchymal- Heart failure to-epithelial transition (MET). Errors in these processes contribute to congenital heart disease, and exert GPCR Epithelial to Mesenchymal Transformation deleterious effects on the heart and circulation after myocardial infarction. The identification of factors (EMT) that are involved in heart development and disease, and the development of new approaches for the Cardiac progenitor cells, Cardiac stem cells treatment of these disorders are of great interest. G protein coupled receptors (GPCRs) comprise 40% of Prokineticin clinically used drug targets, and their signaling are vital components of the heart during development, Apelin, Serotonin cardiac repair and in cardiac disease pathogenesis. This review focuses on the importance of EMT pro- Sphingosine-1-phosphate gram in the heart, and outlines the newly identified GPCRs as potential therapeutic targets of reprogram- ming EMT to support cardiac cell fate during heart development and after myocardial infarction.
    [Show full text]
  • Prokineticin Receptor 1 As a Novel Suppressor of Preadipocyte Proliferation and Differentiation to Control Obesity
    Prokineticin Receptor 1 as a Novel Suppressor of Preadipocyte Proliferation and Differentiation to Control Obesity Ce´cilia Szatkowski1., Judith Vallet1., Mojdeh Dormishian1., Nadia Messaddeq2, Phillippe Valet3, Mounia Boulberdaa1, Daniel Metzger2, Pierre Chambon2, Canan G. Nebigil1* 1 Institute of Research and Biotechnology of Strasbourg, Centre national de la recherche scientifique, UMR7242, University of Strasbourg, Medalis/Labex, Drug Discovery Center, Illkirch, France, 2 Institute of Genetic and Molecular and Cellular Biology, Centre national de la recherche scientifique UMR7104, Institut National de la Sante´ et de la Recherche Me´dicale U964, University of Strasbourg, Illkirch, France, 3 Institutes of Cardiovascular and Metabolic Diseases, Institut National de la Sante´ et de la Recherche Me´dicale–University of Paul Sabatier UMR 1048, Toulouse, France Abstract Background: Adipocyte renewal from preadipocytes occurs throughout the lifetime and contributes to obesity. To date, little is known about the mechanisms that control preadipocyte proliferation and differentiation. Prokineticin-2 is an angiogenic and anorexigenic hormone that activate two G protein-coupled receptors (GPCRs): PKR1 and PKR2. Prokineticin- 2 regulates food intake and energy metabolism via central mechanisms (PKR2). The peripheral effect of prokineticin-2 on adipocytes/preadipocytes has not been studied yet. Methodology/Principal Findings: Since adipocytes and preadipocytes express mainly prokineticin receptor-1 (PKR1), here, we explored the role of PKR1 in adipose tissue expansion, generating PKR1-null (PKR12/2) and adipocyte-specific (PKR1ad2/ 2) mutant mice, and using murine and human preadipocyte cell lines. Both PKR12/2 and PKR1ad2/2 had excessive abdominal adipose tissue, but only PKR12/2 mice showed severe obesity and diabetes-like syndrome. PKR1ad2/2) mice had increased proliferating preadipocytes and newly formed adipocyte levels, leading to expansion of adipose tissue.
    [Show full text]
  • Privileged Frameworks from Snake Venom
    Cell. Mol. Life Sci. (2015) 72:1939–1958 DOI 10.1007/s00018-015-1844-z Cellular and Molecular Life Sciences REVIEW Privileged frameworks from snake venom T. A. Reeks • B. G. Fry • P. F. Alewood Received: 17 December 2014 / Revised: 22 January 2015 / Accepted: 26 January 2015 / Published online: 19 February 2015 Ó Springer Basel 2015 Abstract Venom as a form of chemical prey capture is a Introduction key innovation that has underpinned the explosive ra- diation of the advanced snakes (Caenophidia). Small While venom in reptiles had a single, early evolution [1, 2], venom proteins are often rich in disulfide bonds thus it is at the base of the advanced snakes that it truly became facilitating stable molecular scaffolds that present key a key evolutionary innovation that underpinned the ex- functional residues on the protein surface. New toxin types plosive radiation of this lineage [3]. Snake venom is a are initially developed through the venom gland over-ex- complex mixture of enzymes, proteins and peptides. Many pression of normal body proteins, their subsequent gene of these toxin families have stable molecular scaffolds duplication and diversification that leads to neofunction- (Table 1). The toxins within the venom are a result of gene alisation as random mutations modify their structure and duplication of proteins or peptides typically used elsewhere function. This process has led to preferentially selected in the body, with the copy being selectively expressed in (privileged) cysteine-rich scaffolds that enable the snake to the venom gland [4]. These genes are often amplified into build arrays of toxins many of which may lead to multi-gene families with diverse neofunctionalisation fol- therapeutic products and research tools.
    [Show full text]
  • New Insights Into Metabolic Homeostasis Keith Tan
    Rockefeller University Digital Commons @ RU Student Theses and Dissertations 2015 Activity Based Profiling: New Insights into Metabolic Homeostasis Keith Tan Follow this and additional works at: http://digitalcommons.rockefeller.edu/ student_theses_and_dissertations Part of the Life Sciences Commons Recommended Citation Tan, Keith, "Activity Based Profiling: New Insights into Metabolic Homeostasis" (2015). Student Theses and Dissertations. Paper 285. This Thesis is brought to you for free and open access by Digital Commons @ RU. It has been accepted for inclusion in Student Theses and Dissertations by an authorized administrator of Digital Commons @ RU. For more information, please contact [email protected]. ACTIVITY BASED PROFILING: NEW INSIGHTS INTO METABOLIC HOMEOSTASIS A Thesis Presented to the Faculty of The Rockefeller University in Partial Fulfillment of the Requirements for the degree of Doctor of Philosophy by Keith Tan June 2015 © Copyright by Keith Tan 2015 ACTIVITY BASED PROFILING: NEW INSIGHTS INTO METABOLIC HOMEOSTASIS Keith Tan, Ph.D. The Rockefeller University 2015 There is mounting evidence that demonstrates that body weight and energy homeostasis is tightly regulated by a physiological system. This system consists of sensing and effector components that primarily reside in the central nervous system and disruption to these components can lead to obesity and metabolic disorders. Although many neural substrates have been identified in the past decades, there is reason to believe that there are numerous unidentified neural populations that play a role in energy balance. Besides regulating caloric consumption and energy expenditure, neural components that control energy homeostasis are also tightly intertwined with circadian rhythmicity but this aspect has received less attention.
    [Show full text]
  • Modeling of Human Prokineticin Receptors: Interactions with Novel Small-Molecule Binders and Potential Off- Target Drugs
    Modeling of Human Prokineticin Receptors: Interactions with Novel Small-Molecule Binders and Potential Off- Target Drugs Anat Levit1,2, Talia Yarnitzky1, Ayana Wiener1, Rina Meidan2, Masha Y. Niv1,3* 1 Institute of Biochemistry, Food Science and Nutrition, Faculty of Agriculture, Food and Environment, The Hebrew University of Jerusalem, Rehovot, Israel, 2 Department of Animal Sciences, Faculty of Agriculture, Food and Environment, The Hebrew University of Jerusalem, Rehovot, Israel, 3 The Fritz Haber Center for Molecular Dynamics, The Hebrew University of Jerusalem, Jerusalem, Israel Abstract Background and Motivation: The Prokineticin receptor (PKR) 1 and 2 subtypes are novel members of family A GPCRs, which exhibit an unusually high degree of sequence similarity. Prokineticins (PKs), their cognate ligands, are small secreted proteins of ,80 amino acids; however, non-peptidic low-molecular weight antagonists have also been identified. PKs and their receptors play important roles under various physiological conditions such as maintaining circadian rhythm and pain perception, as well as regulating angiogenesis and modulating immunity. Identifying binding sites for known antagonists and for additional potential binders will facilitate studying and regulating these novel receptors. Blocking PKRs may serve as a therapeutic tool for various diseases, including acute pain, inflammation and cancer. Methods and Results: Ligand-based pharmacophore models were derived from known antagonists, and virtual screening performed on the DrugBank dataset identified potential human PKR (hPKR) ligands with novel scaffolds. Interestingly, these included several HIV protease inhibitors for which endothelial cell dysfunction is a documented side effect. Our results suggest that the side effects might be due to inhibition of the PKR signaling pathway.
    [Show full text]